Financial Performance - The company recorded revenue of SGD 3.9 million for the three months ended March 31, 2021, an increase of approximately 14.6% compared to SGD 3.4 million for the same period in 2020[5] - Gross profit for the period was SGD 2.6 million, up about 6.8% from SGD 2.5 million in the same period last year[5] - The net profit after tax was approximately SGD 228,000, a significant increase from SGD 95,000 in the previous year, despite rising employee benefits and operating expenses[5] - The total comprehensive income for the period attributable to the owners of the company was SGD 228,000, compared to SGD 94,609 in the previous year[8] - Revenue for the first quarter of 2021 increased by approximately SGD 0.5 million or 14.6% to about SGD 3.9 million compared to the same period in 2020[29] - Treatment services generated revenue of SGD 2,823,280, accounting for 71.5% of total revenue, while medical examination services and consultation services contributed SGD 811,025 and SGD 314,777, respectively[19] - Basic earnings per share for the first quarter of 2021 were SGD 0.00, a decrease from SGD 0.02 in the same period last year[26] - The group recorded a profit of approximately SGD 228,000, a decrease of over 90% compared to SGD 940,000 in Q1 2020[40] Operating Expenses - Employee benefits expenses increased by approximately 8.1% to SGD 1.4 million due to efforts to attract and retain talent for expansion plans[5] - Other operating expenses rose by approximately 69.8% to SGD 0.9 million, attributed to increased promotional activities and the expansion of medical treatment centers from 7 to 10[5] - The increase in operating expenses is primarily due to the operation of more clinics, leading to higher marketing and rental costs[39] - Employee benefits expenses increased by approximately SGD 100,000 or 8.1% to about SGD 1.4 million due to efforts to retain and attract talent for expansion plans[40] - Other operating expenses rose by approximately SGD 400,000 or 69.8% to about SGD 900,000, attributed to increased investments in marketing and promotion activities[40] Dividends and Equity - The board has decided not to declare any dividends for the period, consistent with the previous year[6] - The company’s total equity as of March 31, 2021, was SGD 13.26 million, reflecting the retained earnings and comprehensive income for the period[9] Corporate Structure and Strategy - The company has undergone internal restructuring, acquiring six medical treatment centers, which has been accounted for as a common control transaction[13] - The company continues to focus on expanding its network of medical treatment centers in Singapore to enhance its market presence[11] - The company operates nine DTAP clinics and one S Aesthetic clinic, with plans to expand brand awareness and assess new potential locations[31] - The company has terminated the lease agreement for its Orchard location and is currently seeking alternative premises[31] Financial Position - As of March 31, 2021, the group's cash and cash equivalents were approximately SGD 12.2 million, down from SGD 13.1 million as of December 31, 2020[43] - The capital debt ratio as of March 31, 2021, was 19.0%, a decrease from 20.8% as of December 31, 2020[44] - The group maintained a strong liquidity position with sufficient financial resources to meet operational funding needs[44] Employment and Compliance - The group had 64 employees in Singapore as of March 31, 2021, down from 66 employees as of December 31, 2020[42] - The audit committee, consisting of three independent non-executive directors, reviewed the unaudited consolidated financial statements and found them compliant with applicable accounting standards and regulations[70] - There were no significant contingent liabilities as of March 31, 2021[48] Shareholding - As of March 31, 2021, Cher Sen holds 390,000,000 shares, representing 75% of the total issued shares of 520,000,000[64] - The company did not repurchase any of its listed securities during the reporting period[68]

Financial Performance - The group's revenue for the fiscal year ended December 31, 2020, was approximately SGD 13.7 million, a slight increase of about 1.9% compared to SGD 13.5 million for the fiscal year 2019[11]. - The group recorded a profit of approximately SGD 66,000 for the fiscal year 2020, compared to a profit of SGD 600,000 in fiscal year 2019, primarily due to the impact of COVID-19 on expected revenue and increased operating costs from three new treatment centers[11]. - The group's total revenue for the fiscal year 2020 was approximately SGD 13,724,000, an increase of SGD 262,000 or 1.9% compared to SGD 13,462,000 in fiscal year 2019[19]. - Total comprehensive income for the year was approximately SGD 44,000, a decrease from SGD 638,000 in the previous fiscal year, primarily due to the impact of Covid-19 and increased operating costs from the opening of three new treatment centers[36]. - The group reported a net cash inflow from operating activities of approximately SGD 0.8 million, compared to a net cash outflow of SGD 2.7 million in the previous fiscal year[38]. - The group’s total equity as of December 31, 2020, was approximately SGD 13.3 million, slightly up from SGD 13.2 million in the previous fiscal year[38]. - The group did not declare a final dividend for the year, consistent with the previous fiscal year[37]. - The company had no distributable reserves as of December 31, 2020, consistent with the previous year[99]. Revenue Breakdown - Revenue from consultation services decreased from approximately SGD 1,355,000 in 2019 to SGD 1,296,000 in 2020, a decline of about 4.4%[21]. - Revenue from medical examination services fell from approximately SGD 4,040,000 in 2019 to approximately SGD 3,382,000 in 2020, a decrease of about 16.3%[22]. - Revenue from treatment services increased from approximately SGD 8,067,000 in 2019 to approximately SGD 9,046,000 in 2020, a growth of about 12.1%[22]. - The group’s treatment services accounted for 65.9% of total revenue in 2020, up from 59.9% in 2019, indicating a shift in revenue contribution[22]. Operational Expansion - The group operates a network of ten DTAP treatment centers and one SA treatment center, with plans to establish at least two additional treatment centers in the fiscal year 2021[12]. - The group launched a treatment center in Tanjong Pagar in fiscal year 2020, providing rapid STD and HIV testing services[12]. - The group opened three new treatment centers (Kovan, Orchard, and Tanjong Pagar), contributing to improved revenue despite challenges from Covid-19[18]. - The group aims to expand its market share in primary care and seeks to explore business opportunities outside of Singapore to become a preferred healthcare provider in Asia[13]. - The group aims to expand its market share in the primary healthcare sector through its brand DTAP (Dr. Tan & Partners) as demand for healthcare services in Singapore is expected to grow[18]. Expense Management - Employee benefits expenses increased by SGD 1,759,000 or 38.6% to SGD 6,311,000 due to increased staffing for the new treatment centers[27]. - Other operating expenses rose by approximately SGD 458,000 or 18.2% to about SGD 3,000,000, largely driven by increased marketing expenditures[31]. - The group will continue to manage expenses effectively and streamline workflows to improve productivity and ensure financial sustainability[13]. Corporate Governance - The board of directors experienced changes, with Mr. Liu Wei Hung replacing Mr. Leung Ho Shan as the chairman of the audit committee[14]. - The company has a strong management team with extensive experience in finance and healthcare sectors[75]. - The board of directors consists of four members, with independent non-executive directors making up over 50% of the board[155]. - All independent non-executive directors confirmed their independence in accordance with GEM listing rules, ensuring compliance with the requirement for independent oversight[156]. - The company has implemented a fair disclosure policy to ensure compliance with GEM listing rules and has strict measures against unauthorized use of confidential information[200]. Shareholder Information - As of December 31, 2020, the total number of shares issued by the company was 520,000,000[129]. - Dr. Chen holds 390,000,000 shares, representing 75% of the company's issued shares[128]. - Cher Sen Holdings Limited, fully owned by Dr. Chen, is the direct shareholder of the company with 390,000,000 shares[131]. - The company maintains sufficient public float, with at least 25% of its issued shares held by the public as per GEM listing rules[134]. Risk Management - The company has established policies and procedures for risk management and internal controls, ensuring the effectiveness of these systems[195]. - The board of directors is responsible for overseeing the risk management and internal control systems, which are deemed adequate and effective for the review period[195]. - The company has a structured approach to managing risks associated with its daily operations, with management identifying risks for board review[195]. Audit and Compliance - The audit committee, consisting of three independent non-executive directors, reviewed the annual audited consolidated financial statements and deemed them to be properly prepared in accordance with applicable accounting standards and GEM listing rules[145]. - Baker Tilly TFW LLP was appointed as the independent auditor for the fiscal year ending December 31, 2018, and will be proposed for reappointment at the 2021 annual general meeting[147]. - The total remuneration for the independent auditor for the year ended December 31, 2020, was SGD 140,000 for audit services[191]. - The company has complied with all relevant laws and regulations without any major violations during the year[138].

第三季度 報告 香港聯合交易所有限公司GEM（分 別 稱 為「聯 交 所」及 「GEM」）的特色 GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起 其他在聯交所上市的公司帶有較高投資風險。有意投資者應了解投資 於該等公司的潛在風險，並應經過審慎周詳考慮後方作出投資決定。 2020年財務摘要（未經審核） 本集團於截至2020年9月30日止九個月（「本期間」）錄得收益約9.6百萬新加坡元，較2019 年同期（「去年同期」）約為9.8百萬新加坡元減少約1.7%。 本集團於本期間的毛利約為6.8百萬新加坡元，與去年同期約6.9百萬新加坡元維持相同。 本集團於本期間錄得除稅後淨溢利約0.3百萬新加坡元，較去年同期約為1.3百萬新加坡 元減少約75.7%。除稅後溢利減少主要是由於本期間僱員福利開支大幅增加所致。於本 期間僱員福利開支約為4.0百萬新加坡元，較去年同期約3.2百萬新加坡元增加約25.1%， 此乃主要歸因於招聘新醫生、美容師及診治中心助理。 董事會（「董事會」）已議決不就本期間宣派股息（去年同期：無）。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會承受 較於聯交所主板買賣的證券為 ...

[Company Information](index=4&type=section&id=Company%20Information) [Financial Statements and Summary](index=6&type=section&id=Financial%20Statements%20and%20Summary) [2020 Financial Highlights](index=6&type=section&id=2020%20Financial%20Highlights%20(Unaudited)) In H1 2020, the company's total revenue decreased by 11.2% to SGD 5.6 million due to COVID-19 and Singapore's 'circuit breaker' measures, primarily from reduced medical examination services, resulting in a net loss of approximately SGD 0.5 million despite a slight gross profit increase Key Financial Indicators for H1 2020 | Indicator | For the six months ended June 30 | Year-on-Year Change | | :--- | :--- | :--- | | **Revenue** | 5.6 SGD million | -11.2% | | **Gross Profit** | 4.0 SGD million | +1.4% | | **Net (Loss)/Profit After Tax** | (0.5) SGD million | Shift from profit to loss | | **Interim Dividend** | None | No change | - The decline in revenue was primarily due to the COVID-19 pandemic and Singapore's 'circuit breaker' measures, which reduced revenue from medical examination services from **SGD 2.0 million** in the prior period to **SGD 1.4 million**[10](index=10&type=chunk) - The net loss was mainly attributed to a **41.3% year-on-year increase** in employee benefits expenses (approximately **SGD 0.8 million**) for planned DTAP clinic expansion, alongside operational challenges posed by the pandemic[11](index=11&type=chunk) [Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income](index=7&type=section&id=Unaudited%20Condensed%20Consolidated%20Statement%20of%20Profit%20or%20Loss%20and%20Other%20Comprehensive%20Income) For the six months ended June 30, 2020, the company reported a net loss of SGD 0.577 million, a shift from a net profit of SGD 0.557 million in the prior year, primarily due to decreased revenue and increased employee benefits expenses Condensed Consolidated Statement of Profit or Loss (For the six months ended June 30) | Item | 2020 (Unaudited) | 2019 (Unaudited) | | :--- | :--- | :--- | | Revenue | 5,553,010 SGD | 6,250,853 SGD | | Employee Benefits Expenses | (2,796,456) SGD | (1,979,039) SGD | | Loss/Profit Before Income Tax | (333,137) SGD | 628,184 SGD | | **Net Loss/Profit for the Period** | **(576,744) SGD** | **556,884 SGD** | | **Basic and Diluted Loss/Earnings Per Share** | **(0.11) Singapore cents** | **0.11 Singapore cents** | [Unaudited Condensed Consolidated Statement of Financial Position](index=8&type=section&id=Unaudited%20Condensed%20Consolidated%20Statement%20of%20Financial%20Position) As of June 30, 2020, total assets decreased to SGD 17.32 million from SGD 18.63 million at year-end 2019, with total liabilities decreasing to SGD 4.70 million and net assets at SGD 12.63 million Summary of Condensed Consolidated Statement of Financial Position | Item | June 30, 2020 (Unaudited) | December 31, 2019 (Audited) | | :--- | :--- | :--- | | Total Assets | 17,324,626 SGD | 18,634,142 SGD | | Total Liabilities | 4,698,385 SGD | 5,421,961 SGD | | **Net Assets** | **12,626,241 SGD** | **13,212,181 SGD** | | Cash and Cash Equivalents | 12,073,172 SGD | 5,910,074 SGD | [Unaudited Condensed Consolidated Statement of Changes in Equity](index=10&type=section&id=Unaudited%20Condensed%20Consolidated%20Statement%20of%20Changes%20in%20Equity) As of June 30, 2020, total equity decreased from SGD 13.21 million at the beginning of the year to SGD 12.63 million, primarily due to a SGD 0.577 million loss and SGD 0.009 million exchange loss during the period - Total equity attributable to owners of the company decreased from **SGD 13,212,181** at the beginning of 2020 to **SGD 12,626,241** at the end of the period[17](index=17&type=chunk) - The decrease in equity was primarily due to a loss of **SGD 576,744** and an other comprehensive income loss (exchange differences) of **SGD 9,196** recorded during the fiscal period[17](index=17&type=chunk) [Unaudited Condensed Consolidated Statement of Cash Flows](index=11&type=section&id=Unaudited%20Condensed%20Consolidated%20Statement%20of%20Cash%20Flows) In H1 2020, net cash outflow from operating activities was SGD 0.755 million, while investing activities generated SGD 7.77 million net cash inflow, primarily from maturing financial assets, increasing period-end cash and cash equivalents to SGD 12.07 million Summary of Condensed Consolidated Statement of Cash Flows (For the six months ended June 30) | Item | 2020 (Unaudited) | 2019 (Unaudited) | | :--- | :--- | :--- | | Net Cash (Used in)/From Operating Activities | (755,041) SGD | 1,436,291 SGD | | Net Cash From/(Used in) Investing Activities | 7,769,848 SGD | (280,609) SGD | | Net Cash Used in Financing Activities | (851,711) SGD | – | | **Cash and Cash Equivalents at End of Period** | **12,073,170 SGD** | **13,526,025 SGD** | [Notes to the Unaudited Condensed Consolidated Financial Statements](index=12&type=section&id=Notes%20to%20the%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) [1 General Information and Reorganization](index=12&type=section&id=1%20General%20Information%20and%20Reorganization) The company, an investment holding company registered in Cayman Islands, primarily operates medical clinics in Singapore and listed on HK GEM in 2018, undergoing internal business reorganization during the reporting period involving clinic acquisitions treated as common control business combinations - The Group primarily operates medical clinics and provides management consultancy services in Singapore[21](index=21&type=chunk) - On April 1, 2020, the Group completed several internal acquisitions of clinic businesses, which were accounted for as common control business combinations[23](index=23&type=chunk) [2 Basis of Presentation and Accounting Policies](index=13&type=section&id=2%20Basis%20of%20Presentation%20and%20Accounting%20Policies) These unaudited condensed consolidated financial statements are prepared in accordance with IFRS, applying consistent accounting policies as the 2019 audited statements, with no significant impact from new standards, and Singapore Dollars as the functional and presentation currency - The unaudited condensed consolidated financial statements have been prepared in accordance with all applicable International Financial Reporting Standards (IFRS) and the disclosure requirements of the GEM Listing Rules[24](index=24&type=chunk) - The Group's functional and presentation currency is the Singapore Dollar[26](index=26&type=chunk) [3 Revenue](index=19&type=section&id=3%20Revenue) Total revenue for H1 2020 was SGD 5.55 million, a 11.2% year-on-year decrease, primarily driven by a significant decline in medical examination services revenue from SGD 2.02 million to SGD 1.42 million Revenue Analysis by Business Activity (For the six months ended June 30) | Type of Medical Service | 2020 (Unaudited) | 2019 (Unaudited) | Year-on-Year Change | | :--- | :--- | :--- | :--- | | Treatment Services | 3,576,321 SGD | 3,613,779 SGD | -1.0% | | Medical Examination Services | 1,416,469 SGD | 2,020,776 SGD | -29.9% | | Consultation Services | 560,220 SGD | 616,298 SGD | -9.1% | | **Total** | **5,553,010 SGD** | **6,250,853 SGD** | **-11.2%** | [4 Income Tax Expense](index=20&type=section&id=4%20Income%20Tax%20Expense) For the six months ended June 30, 2020, the Group's current income tax expense was SGD 0.244 million, an increase from SGD 0.071 million in the prior year, with Singapore corporate income tax rate at 17% - Current Singapore income tax for the six months ended June 30, 2020, was **SGD 243,607**, compared to **SGD 71,300** for the same period in 2019[49](index=49&type=chunk) [5 Loss/Earnings Per Share](index=21&type=section&id=5%20Loss%2FEarnings%20Per%20Share) For the six months ended June 30, 2020, basic and diluted loss per share was 0.11 Singapore cents, a shift from earnings per share of 0.11 Singapore cents in the prior year, calculated based on 520 million weighted average ordinary shares Loss/Earnings Per Share Calculation | Item | For the six months ended June 30 (2020) | For the six months ended June 30 (2019) | | :--- | :--- | :--- | | (Loss)/Profit Attributable to Owners of the Company | (585,940) SGD | 556,884 SGD | | Weighted Average Number of Ordinary Shares | 520,000,000 | 520,000,000 | | **Loss/Earnings Per Share (Singapore cents)** | **(0.11)** | **0.11** | [Notes to Key Financial Statement Items](index=22&type=section&id=Notes%20to%20Key%20Financial%20Statement%20Items) This section details changes in key balance sheet items, including property, plant and equipment, right-of-use assets, receivables, payables, and cash [6 Property, Plant and Equipment](index=22&type=section&id=6%20Property%2C%20Plant%20and%20Equipment) As of June 30, 2020, the net book value of property, plant and equipment decreased to SGD 0.558 million from SGD 0.695 million at the beginning of the year, primarily due to SGD 0.217 million in depreciation during the period - As of June 30, 2020, the net book value of property, plant and equipment was **SGD 558,398**, lower than **SGD 694,504** at the beginning of 2020[55](index=55&type=chunk)[57](index=57&type=chunk) [7 Right-of-Use Assets and Lease Liabilities](index=24&type=section&id=7%20Right-of-Use%20Assets%20and%20Lease%20Liabilities) As of June 30, 2020, right-of-use assets had a book value of SGD 1.93 million and lease liabilities were SGD 1.77 million, primarily related to the Group's leased office and clinic units - As of June 30, 2020, the book value of right-of-use assets was **SGD 1,928,952**, and the book value of lease liabilities was **SGD 1,772,129**[59](index=59&type=chunk) [8 Trade and Other Receivables](index=26&type=section&id=8%20Trade%20and%20Other%20Receivables) Trade receivables increased from SGD 0.094 million at the beginning of the year to SGD 0.126 million, while current deposits, prepayments, and other receivables significantly rose from SGD 0.765 million to SGD 2.02 million - Trade receivables increased from **SGD 94,082** at the end of 2019 to **SGD 125,800** as of June 30, 2020[60](index=60&type=chunk) [12 Cash and Cash Equivalents](index=28&type=section&id=12%20Cash%20and%20Cash%20Equivalents) As of June 30, 2020, total cash and cash equivalents significantly increased to SGD 12.07 million from SGD 5.91 million at the end of 2019 - Cash and cash equivalents significantly increased from **SGD 5,910,074** at the end of 2019 to **SGD 12,073,172** as of June 30, 2020[65](index=65&type=chunk) [14 Trade and Other Payables](index=29&type=section&id=14%20Trade%20and%20Other%20Payables) Trade payables increased from SGD 0.795 million at the beginning of the year to SGD 0.857 million, while accrued expenses and other payables rose from SGD 0.706 million to SGD 0.861 million - Trade payables increased from **SGD 794,940** at the end of 2019 to **SGD 857,350** as of June 30, 2020[68](index=68&type=chunk) [Share Capital and Dividends](index=30&type=section&id=16%20Equity%20%26%2017%20Dividends) As of June 30, 2020, the company had 520 million issued ordinary shares with a share capital of SGD 0.897 million, and the Board resolved not to declare an interim dividend for the period - As of June 30, 2020, the company had **520,000,000** issued and fully paid ordinary shares[70](index=70&type=chunk) - The Board has resolved not to declare an interim dividend for the period, consistent with the prior year[71](index=71&type=chunk) [18 Related Party Transactions](index=30&type=section&id=18%20Related%20Party%20Transactions) During the reporting period, total remuneration paid to key management significantly increased to SGD 0.301 million from SGD 0.170 million in the prior year, primarily due to higher salaries, allowances, and benefits in kind Key Management Remuneration (For the six months ended June 30) | Item | 2020 (Unaudited) | 2019 (Unaudited) | | :--- | :--- | :--- | | Salaries, Allowances and Benefits in Kind | 217,609 SGD | 77,652 SGD | | Directors' Fees | 72,000 SGD | 82,033 SGD | | Contributions to Defined Contribution Plans | 11,278 SGD | 9,860 SGD | | **Total** | **300,887 SGD** | **169,545 SGD** | [Management Discussion and Analysis](index=32&type=section&id=Management%20Discussion%20and%20Analysis) [Business Review and Outlook](index=32&type=section&id=Business%20Review%20and%20Outlook) The company, a leading general medical network in Singapore operating under the 'DTAP' brand, experienced an 11.2% year-on-year revenue decline in H1 2020 due to COVID-19 'circuit breaker' measures, but plans to expand market share and strengthen its brand despite ongoing pandemic uncertainties - Revenue for H1 2020 decreased by **11.2%** year-on-year to approximately **SGD 5.6 million**, primarily impacted by the COVID-19 pandemic and 'circuit breaker' measures in Singapore[77](index=77&type=chunk) - Looking ahead, the pandemic outbreak presents uncertainties and operational challenges for clinics, but the Group will continue to seek market share expansion and enhance the DTAP brand and business[78](index=78&type=chunk) - As of the reporting date, the Group operates **9** clinics, with another one awaiting approval from the Ministry of Health[80](index=80&type=chunk) [Financial Review](index=33&type=section&id=Financial%20Review) H1 2020 revenue decreased by 11.2% to SGD 5.6 million due to reduced medical examination services, while gross profit margin improved from 62.9% to 71.8% as high-cost services declined, but a 41.3% increase in employee benefits expenses for planned expansion led to a net loss of approximately SGD 0.6 million - Revenue decreased by **11.2%** from **SGD 6.3 million** in the prior period to **SGD 5.6 million** in the current period, primarily due to the impact of COVID-19 and 'circuit breaker' measures[81](index=81&type=chunk) - Gross profit margin increased from **62.9%** in the prior period to **71.8%** in the current period, mainly due to a **58.6%** significant reduction in medical professional costs resulting from changes in service mix[83](index=83&type=chunk) - Employee benefits expenses increased by **41.3%** year-on-year (approximately **SGD 0.8 million**), primarily attributed to the recruitment of new staff for the planned expansion of DTAP clinics[84](index=84&type=chunk) - The period recorded a loss of approximately **SGD 0.6 million**, compared to a profit of approximately **SGD 0.6 million** in the prior period, mainly due to pandemic challenges and increased employee benefits expenses[87](index=87&type=chunk) [Liquidity and Capital Resources](index=35&type=section&id=Liquidity%2C%20Financial%20Resources%20and%20Fundraising) The company's working capital is primarily derived from internal cash flow, with cash and cash equivalents of approximately SGD 12.1 million and no bank borrowings as of June 30, 2020, resulting in a decrease in the capital gearing ratio from 18.6% to 14.0% Liquidity and Capital Gearing Ratio | Indicator | June 30, 2020 | December 31, 2019 | | :--- | :--- | :--- | | Cash and Cash Equivalents | 12.1 SGD million | 5.9 SGD million | | Bank Borrowings | None | None | | Capital Gearing Ratio | 14.0% | 18.6% | [Use of Proceeds](index=38&type=section&id=Use%20of%20Proceeds) Of the approximately SGD 9.1 million net proceeds from the company's listing, SGD 2.14 million had been utilized as of June 30, 2020, with some expansion plans, such as new 'DTAP' and 'SA' clinics, delayed due to the pandemic and market conditions Use of Net Proceeds from Listing (As of June 30, 2020) | Purpose | Net Proceeds from Listing (SGD thousands) | Amount Utilized (SGD thousands) | Balance (SGD thousands) | | :--- | :--- | :--- | :--- | | Expansion of DTAP Clinic Network | 2,600 | 572 | 2,028 | | Establishment of New SA Clinics | 1,400 | 173 | 1,227 | | Attracting and Retaining Talent | 4,300 | 1,091 | 3,209 | | Enhancing IT Infrastructure | 600 | 205 | 395 | | Establishing Central Pharmacy | 100 | – | 100 | | General Working Capital | 100 | 100 | – | | **Total** | **9,100** | **2,141** | **6,959** | - Plans to open new 'DTAP' clinics were postponed due to availability of leased space, while plans for new 'SA' clinics were delayed until H2 2022 due to market saturation in Singapore's aesthetic clinic sector[108](index=108&type=chunk) [Corporate Governance and Other Information](index=42&type=section&id=Corporate%20Governance%20and%20Other%20Information) [Corporate Governance Practices](index=42&type=section&id=Corporate%20Governance%20Practices) The company complied with all applicable provisions of the GEM Listing Rules' Corporate Governance Code during the reporting period, adopted a code of conduct for directors' securities transactions, and confirmed no share options have been granted since the adoption of the share option scheme - The company has adopted and complied with all applicable code provisions of the Corporate Governance Code in Appendix 15 to the GEM Listing Rules during the period[113](index=113&type=chunk) - No share options have been granted or agreed to be granted by the company since the adoption of the share option scheme up to the date of this report[115](index=115&type=chunk) [Directors' and Shareholders' Interests](index=43&type=section&id=Directors'%20and%20Chief%20Executive's%20Interests%20and%20Short%20Positions%20in%20Shares%2C%20Underlying%20Shares%20and%20Debentures%20of%20the%20Company%20and%20its%20Associated%20Corporations) As of June 30, 2020, Dr. Chan Cher Sen, Chairman and Executive Director, held 390 million shares, representing 75% of the issued share capital, through his wholly-owned company Cher Sen Holdings Limited, making him the controlling shareholder - Dr. Chan Cher Sen, Chairman and Executive Director, is deemed to have an interest in **390,000,000** shares held by his wholly-owned company, Cher Sen Holdings Limited, representing **75%** of the company's issued shares[117](index=117&type=chunk)[118](index=118&type=chunk) - Cher Sen Holdings Limited, as beneficial owner, holds a long position of **390,000,000** shares in the company, representing **75%**[122](index=122&type=chunk) [Audit Committee Review](index=46&type=section&id=Audit%20Committee%20Review) The Audit Committee, comprising three independent non-executive directors, has reviewed the Group's unaudited condensed consolidated financial statements and this interim report, confirming their preparation in compliance with applicable accounting standards and listing rules, with sufficient disclosures - The Audit Committee, composed of three independent non-executive directors, has reviewed the unaudited condensed consolidated financial statements and this report[129](index=129&type=chunk) - The Audit Committee believes that these statements and the report have been prepared in compliance with applicable accounting standards, GEM Listing Rules, and other legal requirements, with adequate disclosures[129](index=129&type=chunk)

Financial Performance - The company recorded revenue of approximately SGD 3.4 million for the three months ended March 31, 2020, an increase of about 21.1% compared to SGD 2.8 million for the same period in 2019[6]. - Gross profit for the period was approximately SGD 2.5 million, representing a 29.4% increase from SGD 1.9 million in the previous year[6]. - Net profit after tax was approximately SGD 95,000, a decrease from SGD 268,061 in the same period last year, primarily due to an increase in tax expenses of SGD 189,000[7]. - Basic earnings per share decreased from SGD 0.05 to SGD 0.02, with profit attributable to owners of the company falling from SGD 268,221 to SGD 94,609[23]. - The group recorded a profit of approximately SGD 95,000 for the period, a decrease of about SGD 200,000 compared to the profit of approximately SGD 300,000 in Q1 2019[36]. Employee Expenses - Employee benefits expenses increased by approximately 44.9% to about SGD 1.3 million, driven by an increase in the number of employees[6]. - Employee benefits expenses increased by approximately SGD 0.4 million or 44.9% to about SGD 1.3 million, primarily due to the hiring of new doctors and staff[32]. - The group had 53 employees in Singapore as of March 31, 2020, compared to 51 employees as of December 31, 2019[39]. Operating Expenses - Other operating expenses increased by approximately SGD 115,000, mainly due to increased marketing efforts and advertising to enhance market awareness[6]. - Other operating expenses increased by approximately SGD 115,000 due to increased marketing efforts and advertising campaigns to enhance brand awareness[35]. - The company’s operating lease expenses have been impacted by the adoption of IFRS 16, resulting in depreciation being recognized instead of rental expenses[6]. Equity and Cash Position - The total equity attributable to the company’s owners as of March 31, 2020, was SGD 13.3 million, an increase from SGD 12.8 million at the end of the previous year[11]. - As of March 31, 2020, the group's cash and cash equivalents were approximately SGD 12.9 million, up from SGD 5.9 million as of December 31, 2019[40]. - The capital debt ratio as of March 31, 2020, was 17.0%, a decrease from 18.6% as of December 31, 2019[41]. - The group has no bank borrowings as of March 31, 2020[40]. - The group maintains a prudent policy for managing cash reserves to ensure readiness for future growth opportunities[46]. Dividends - The company did not declare any dividends for the period, consistent with the previous year[8]. - The board has resolved not to declare any dividends for the period, consistent with the previous year[38]. Business Expansion - The company is actively expanding its network of medical treatment centers, with recent acquisitions planned for April 2020[15]. - The company operates seven DTAP treatment centers and plans to establish two additional centers post-lockdown[29]. - The company continues to focus on expanding market share and enhancing brand reputation in the healthcare sector despite challenges posed by COVID-19[28]. Compliance and Governance - The audit committee, consisting of three independent non-executive directors, reviewed the unaudited condensed consolidated financial statements and confirmed compliance with applicable accounting standards and GEM listing rules[65]. - The company has established an audit committee in accordance with corporate governance code provisions and GEM listing rules[65]. - The chairman and executive director is Dr. Chen Zhi Xian, with the financial director being Mr. Zhuo Han Wen[66]. - The company has disclosed that there are no conflicts of interest with any directors or controlling shareholders[61]. - The report was dated May 8, 2020, indicating the company's ongoing commitment to transparency and compliance[66]. Tax Expenses - The company reported a current tax expense of SGD 243,607 for the first quarter of 2020, compared to SGD 54,903 in the same period last year[21]. Revenue Composition - Treatment services accounted for approximately 64.5% of total revenue, while medical examination services and consultation services contributed 25.8% and 9.7%, respectively[27]. Accounting Policies - The company has maintained its accounting policies consistent with those used in the preparation of the audited financial statements for 2019[19]. - The company has not experienced significant changes in accounting policies due to the adoption of new or revised International Financial Reporting Standards[19]. Shareholding and Securities - As of March 31, 2020, Cher Sen holds 390,000,000 shares, representing 75% of the total issued shares of 520,000,000[63]. - The company did not redeem any of its listed securities during the period, nor did it or any of its subsidiaries purchase or sell such securities[64]. - There were no other entities, aside from those disclosed, that held interests in the company's shares as of March 31, 2020[60]. - The compliance advisor, Tian Tai Financial Services Limited, reported no interests in the company's securities as of March 31, 2020[62]. - The company has not reported any interests from directors or controlling shareholders in competing businesses during the period[61].

Financial Performance - The group recorded a revenue increase of 29.2%, rising from approximately SGD 10.4 million in the fiscal year 2018 to about SGD 13.5 million in the fiscal year 2019[9]. - The profit for the fiscal year 2019 was approximately SGD 0.6 million, compared to a loss of SGD 0.7 million in the fiscal year 2018[9]. - The total revenue for the year was approximately SGD 13,462,000, an increase of about SGD 3,041,000 or 29.2% compared to SGD 10,421,000 in the 2018 fiscal year[15]. - Revenue from consultation services, medical examination services, and treatment services were approximately SGD 1.355 million, SGD 4.040 million, and SGD 8.067 million, respectively, accounting for 10.1%, 30.0%, and 59.9% of total revenue[14]. - Revenue from diagnostic services increased from approximately SGD 1,057,000 in 2018 to SGD 1,356,000 in the current year, a rise of about SGD 299,000[17]. - Revenue from medical examination services rose from approximately SGD 3,017,000 in 2018 to SGD 4,040,000, an increase of about SGD 1,023,000, maintaining a contribution percentage of around 30.0%[17]. - Revenue from treatment services grew from approximately SGD 6,263,000 in 2018 to SGD 8,067,000, an increase of about SGD 1,804,000, with a stable contribution percentage of approximately 59.9%[17]. - The company recorded a profit of approximately SGD 638,000 for the year, an increase of about SGD 1.4 million compared to a loss of approximately SGD 731,000 in the 2018 fiscal year[31]. - The income tax expense for the year was approximately SGD 462,000, compared to SGD 87,000 in the 2018 fiscal year[29]. Operational Developments - The company plans to establish three new consultation centers in the fiscal year 2020, currently under renovation[10]. - The company operates a network of seven DTAP consultation centers and one SA consultation center as of the report date[10]. - The group expects a challenging and competitive business environment moving forward[10]. - The company aims to expand market share and enhance the Dr. Tan & Partners brand reputation in the healthcare services industry in Singapore[14]. - The group will continue to manage expenses, particularly labor costs, by upgrading and utilizing technology[10]. Employee and Labor Costs - Employee benefits expenses increased by SGD 893,000 or 24.4% to SGD 4,552,000 due to an increase in the number of employees[22]. - The total number of employees increased from 33 in 2018 to 51 in 2019[23]. - Employee costs for the year were approximately SGD 4.6 million, up from SGD 3.7 million in the fiscal year 2018, with a total of 51 employees as of December 31, 2019[43]. Financial Position - Total equity of the group as of December 31, 2019, was approximately SGD 13.2 million, an increase from SGD 12.6 million in the fiscal year 2018[34]. - Cash and bank balances as of December 31, 2019, were approximately SGD 5.9 million, down from SGD 12.4 million in the fiscal year 2018[34]. - Net cash generated from operating activities was approximately SGD 2.7 million, compared to a net cash outflow of SGD 0.3 million in the fiscal year 2018[34]. - The group's capital debt ratio as of December 31, 2019, was 18.6%, a significant increase from 0.0% in the fiscal year 2018[34]. Corporate Governance - The company is committed to maintaining high standards of accountability and ethical conduct in its operations[69]. - The board includes independent non-executive directors with extensive experience in finance and auditing, enhancing corporate governance[69][70]. - The company has adopted and complied with all applicable corporate governance code provisions as per the GEM listing rules for the year ending December 31, 2019[150]. - The company has established a strong internal control and risk management framework to ensure effective accountability[149]. - The company has confirmed that all directors have complied with the trading code as per GEM listing rules during the year[151]. Shareholder Information - The company did not declare a final dividend for the year[33]. - The group did not declare any dividends for the current year, consistent with the previous year[87]. - As of December 31, 2019, the group had no distributable reserves, unchanged from 2018[97]. - The next annual general meeting is scheduled for June 26, 2020, with a suspension of share transfer registration from June 22 to June 26, 2020[88]. Strategic Initiatives - The company aims to expand its market presence and enhance its operational efficiency through strategic initiatives[81]. - The company spent SGD 2.6 million to strategically expand and consolidate the DTAP treatment center network, with SGD 497,000 already utilized by the first half of 2021[54]. - A total of SGD 4.3 million was allocated for the continuous recruitment and retention of doctors and staff, with SGD 1.091 million utilized by the second half of 2021[54]. - The company invested SGD 600,000 to enhance and improve its IT infrastructure, with SGD 176,000 spent by the second half of 2020[54]. Compliance and Legal Matters - The company has confirmed compliance with non-competition agreements by all controlled persons during the year[118]. - The company has not disclosed any significant events that require disclosure after December 31, 2019, up to the date of the report[142]. - The company has complied with all relevant laws and regulations affecting its business operations during the year, with no significant violations reported[138]. Audit and Financial Reporting - The audit committee has reviewed the audited consolidated financial statements for the year and confirmed they were prepared in accordance with applicable accounting standards and GEM listing rules[146]. - Baker Tilly TFW LLP has been appointed as the independent auditor for the company, succeeding PwC, and will be proposed for reappointment at the 2020 annual general meeting[147]. - The external auditor's fees for the year ending December 31, 2019, amounted to SGD 120,000 for audit services, with no fees for non-audit services[191].

[Financial and Operating Highlights](index=4&type=section&id=Financial%20and%20Operating%20Highlights) [2019 Third Quarter Financial Highlights](index=4&type=section&id=2019%E5%B9%B4%E8%B2%A1%E5%8B%99%E6%91%98%E8%A6%81%EF%BC%88%E6%9C%AA%E7%B6%93%E5%AF%A9%E6%A0%B8%EF%BC%89) For the nine months ended September 30, 2019, the Group achieved significant growth in revenue and gross profit, successfully returning to profitability, primarily due to the absence of one-off non-recurring listing expenses incurred in the prior year period, with no interim dividend declared by the Board 2019 Nine-Month Financial Summary | Metric | Nine Months Ended Sep 30, 2019 | Nine Months Ended Sep 30, 2018 | Year-on-Year Change | | :--- | :--- | :--- | :--- | | Revenue | 9.8 million Singapore Dollars | 7.6 million Singapore Dollars | +28.9% | | Gross Profit | 6.9 million Singapore Dollars | 5.1 million Singapore Dollars | +35.3% | | Profit/(Loss) After Tax | 1.3 million Singapore Dollars | (0.9) million Singapore Dollars | Returned to Profitability | | Dividend | None | None | - | - Performance turned profitable from a loss in the prior year period, mainly due to approximately **2.4 million Singapore Dollars** in one-off non-recurring listing expenses incurred in the prior year period[8](index=8&type=chunk) [Management Discussion and Analysis](index=11&type=section&id=%E7%AE%A1%E7%90%86%E5%B1%A4%E8%A8%8E%E8%AB%96%E5%8F%8A%E5%88%86%E6%9E%90) Management reviewed the business and financial performance for the period, outlining future prospects, with the Group operating a clinic network in Singapore under "DTAP" and "SA" brands, planning further expansion using IPO funds, and achieving profitability despite increased staff and operating expenses due to expansion [Business Review and Outlook](index=11&type=section&id=%E6%A5%AD%E5%8B%99%E5%9B%9E%E9%A1%87%E8%88%87%E5%B1%95%E6%9C%9B) The Group operates medical and aesthetic clinic networks in Singapore under the "Dr. Tan & Partners (DTAP)" and "S Aesthetics (SA)" brands, with 9 clinics as of the reporting date, planning future expansion using approximately 9.1 million Singapore Dollars in net IPO proceeds, and focusing on cost control through technology while noting strong demand in niche markets like sexual health and infectious diseases - The Group operates **7 DTAP clinics** and **2 SA aesthetic clinics** in Singapore, with plans to open a new clinic in Bugis[29](index=29&type=chunk) - Approximately **9.1 million Singapore Dollars** in net IPO proceeds are planned for business expansion and growth in Singapore[29](index=29&type=chunk) - Future strategic focus is on managing expenses, particularly by enhancing and leveraging technology to reduce labor intensity and control staff costs[29](index=29&type=chunk) [Financial Review](index=12&type=section&id=%E8%B2%A1%E5%8B%99%E5%9B%9E%E9%A1%87) The period saw strong financial performance, with revenue increasing by **28.9%** year-on-year due to existing service sales growth and brand awareness, gross margin improving from **67.6% to 70.6%** due to effective drug cost control, and the company returning to profitability with a net profit of **1.3 million Singapore Dollars** despite increased staff welfare and other operating expenses - Revenue increased by **28.9%** from **7.6 million Singapore Dollars** to **9.8 million Singapore Dollars** year-on-year, primarily due to increased sales of existing services and market penetration[33](index=33&type=chunk) - Gross margin increased from **67.6% to 70.6%**, mainly due to efforts to reduce drug costs used in treatments[34](index=34&type=chunk) - Staff welfare expenses and other operating expenses increased by **33.3%** and **72.7%** respectively, due to the recruitment of new staff and an increase in the number of clinics[35](index=35&type=chunk)[36](index=36&type=chunk) - The company turned profitable with a net profit of **1.3 million Singapore Dollars** from a loss of **0.9 million Singapore Dollars** in the prior year period, mainly due to approximately **2.4 million Singapore Dollars** in one-off non-recurring listing expenses incurred in the prior year period[37](index=37&type=chunk) [Liquidity and Capital Position](index=13&type=section&id=%E6%B5%81%E5%8B%95%E8%B3%87%E9%87%91%E3%80%81%E8%B2%A1%E5%8B%99%E8%B3%87%E6%BA%90%E5%8F%8A%E9%9B%86%E8%B3%87) The Group primarily meets working capital needs through operating cash flow and shareholder contributions, holding approximately **11.9 million Singapore Dollars** in cash and cash equivalents with no bank borrowings as of September 30, 2019, while the debt-to-equity ratio increased from **12.2% to 19.1%**, and total employees grew from **36 to 53** Liquidity and Capital Position Summary | Metric | Sep 30, 2019 | Dec 31, 2018 | | :--- | :--- | :--- | | Cash and Cash Equivalents | 11.9 million Singapore Dollars | 12.4 million Singapore Dollars | | Bank Borrowings | None | None | | Debt-to-Equity Ratio | 19.1% | 12.2% | | Number of Employees | 53 | 36 | [Unaudited Condensed Consolidated Financial Statements](index=5&type=section&id=Unaudited%20Condensed%20Consolidated%20Financial%20Statements) [Consolidated Statement of Profit or Loss and Other Comprehensive Income](index=5&type=section&id=%E6%9C%AA%E7%B6%93%E5%AF%A9%E6%A0%B8%E7%B0%A1%E6%98%8E%E7%B6%9C%E5%90%88%E6%90%8D%E7%9B%8A%E5%8F%8A%E5%85%B6%E4%BB%96%E5%85%A8%E9%9D%A2%E6%94%B6%E7%9B%8A%E8%A1%A8) For the nine months ended September 30, 2019, the Group's total revenue reached **9.78 million Singapore Dollars**, a **28.6%** year-on-year increase, achieving a pre-tax profit of **1.61 million Singapore Dollars** and a net profit of **1.27 million Singapore Dollars**, reversing a prior year loss of **0.86 million Singapore Dollars** due to revenue growth and cost control in the absence of significant listing expenses Consolidated Statement of Profit or Loss and Other Comprehensive Income | Item (Singapore Dollars) | Nine Months Ended Sep 30, 2019 | Nine Months Ended Sep 30, 2018 | | :--- | :--- | :--- | | Revenue | 9,780,985 | 7,606,621 | | Profit/(Loss) Before Income Tax | 1,606,407 | (864,338) | | Profit/(Loss) for the Period | 1,271,560 | (867,565) | | Basic and Diluted Earnings/(Loss) Per Share | 0.28 cents | (0.19 cents) | [Consolidated Statement of Changes in Equity](index=6&type=section&id=%E6%9C%AA%E7%B6%93%E5%AF%A9%E6%A0%B8%E7%B0%A1%E6%98%8E%E7%B6%9C%E5%90%88%E6%AC%8A%E7%9B%8A%E8%AE%8A%E5%8B%95%E8%A1%A8) As of September 30, 2019, the Group's total equity increased to **13.85 million Singapore Dollars**, primarily driven by the **1.27 million Singapore Dollars** net profit recorded during the period, compared to **12.57 million Singapore Dollars** at the beginning of the year - Total equity increased from **12,574,614 Singapore Dollars** as of January 1, 2019, to **13,846,174 Singapore Dollars** as of September 30, 2019[13](index=13&type=chunk) - The increase in equity is primarily due to the profit of **1,271,560 Singapore Dollars** recorded during the period[13](index=13&type=chunk) [Notes to the Unaudited Condensed Consolidated Financial Statements](index=7&type=section&id=%E6%9C%AA%E7%B6%93%E5%AF%A9%E6%A0%B8%E7%B0%A1%E6%98%8E%E7%B6%9C%E5%90%88%E8%B2%A1%E5%8B%99%E5%A0%B1%E8%A1%A8%E9%99%84%E8%A8%BB) This section provides detailed explanations of the company's basic information, accounting policies, revenue composition, taxation, and earnings per share calculation, noting the company's GEM listing on June 15, 2018, its primary operation of medical centers in Singapore, adherence to International Financial Reporting Standards, and a Singapore income tax rate of **17%** [Revenue Composition](index=9&type=section&id=3%20%E6%94%B6%E7%9B%8A%E5%8F%8A%E5%88%86%E9%83%A8%E6%A5%AD%E7%B8%BE) The Group's total revenue of **9.78 million Singapore Dollars** was entirely derived from medical services, with treatment services being the largest contributor at **5.75 million Singapore Dollars**, followed by medical examination services at **3.04 million Singapore Dollars** and consultation services at **0.99 million Singapore Dollars** Revenue by Service Type | Revenue Source | Nine Months Ended Sep 30, 2019 (Singapore Dollars) | Nine Months Ended Sep 30, 2018 (Singapore Dollars) | | :--- | :--- | :--- | | Treatment Services | 5,753,490 | 4,899,188 | | Medical Examination Services | 3,040,290 | 1,848,500 | | Consultation Services | 987,205 | 790,145 | | **Total** | **9,780,985** | **7,537,833** | [Earnings Per Share](index=10&type=section&id=5%20%E6%AF%8F%E8%82%A1%E7%9B%88%E5%88%A9%E2%88%95%EF%BC%88%E虧%E6%90%8D%EF%BC%89) Basic and diluted earnings per share for the period were **0.28 Singapore cents**, a turnaround from a loss of **0.19 Singapore cents** per share in the prior year period, calculated based on a weighted average of **460,876,000** ordinary shares, with diluted EPS being identical to basic EPS due to the absence of potential dilutive ordinary shares Earnings Per Share Calculation | Item | Nine Months Ended Sep 30, 2019 | Nine Months Ended Sep 30, 2018 | | :--- | :--- | :--- | | Profit/(Loss) Attributable to Owners of the Company | 1,271,560 Singapore Dollars | (867,565) Singapore Dollars | | Weighted Average Number of Ordinary Shares | 460,876,000 | 460,876,000 | | Earnings/(Loss) Per Share | 0.28 Singapore cents | (0.19) Singapore cents | [Corporate Governance and Other Information](index=15&type=section&id=%E4%BC%81%E6%A5%AD%E7%AE%A1%E6%B2%BB%E5%8F%8A%E5%85%B6%E4%BB%96%E8%B3%87%E6%96%99) [Directors' and Major Shareholders' Interests](index=15&type=section&id=%E8%91%A3%E4%BA%8B%E5%8F%8A%E4%B8%BB%E8%82%A1%E6%9D%B1%E6%AC%8A%E7%9B%8A) As of September 30, 2019, Dr. Tan Chee Siang, Chairman and Executive Director, held **75%** of the issued shares through his wholly-owned Cher Sen Holdings Limited, making him the controlling shareholder, with no share options granted since the adoption of the share option scheme - Dr. Tan Chee Siang, Chairman and Executive Director, is deemed to have an interest in **390,000,000 shares**, representing **75%** of the company's issued shares[54](index=54&type=chunk)[57](index=57&type=chunk) - These shares are held by Cher Sen Holdings Limited, which is wholly owned by Dr. Tan[57](index=57&type=chunk)[61](index=61&type=chunk) - No share options have been granted by the company since the adoption of the share option scheme on May 18, 2018[53](index=53&type=chunk) [Compliance and Governance](index=18&type=section&id=%E5%90%88%E8%A6%8F%E8%88%87%E7%AE%A1%E6%B2%BB) The company complied with all applicable code provisions of the GEM Listing Rules' Corporate Governance Code during the reporting period, with an Audit Committee comprising three independent non-executive directors having reviewed the quarterly report, and directors adhering to prescribed standards for securities transactions, with no purchases, sales, or redemptions of the company's listed securities by the company or its subsidiaries during the period - The company complied with all applicable code provisions of the Corporate Governance Code during the period[65](index=65&type=chunk) - The Audit Committee, composed of three independent non-executive directors, has reviewed the unaudited condensed consolidated financial statements and this report[70](index=70&type=chunk) - During the period, neither the company nor any of its subsidiaries purchased, sold, or redeemed any of its listed securities[69](index=69&type=chunk)

Financial Performance - The group recorded revenue of approximately SGD 6.3 million for the six months ended June 30, 2019, an increase of about 13.1% compared to SGD 5.5 million for the same period in 2018[9] - Gross profit for the period remained stable at SGD 3.9 million, consistent with the previous year[10] - The group achieved a net profit after tax of approximately SGD 0.6 million, a significant turnaround from a net loss of SGD 1.5 million in the same period last year, primarily due to a one-time non-recurring listing expense of approximately SGD 2.5 million incurred in the prior year[10] - Total revenue for the six months ended June 30, 2019, was SGD 6,250,853, an increase of 14.5% from SGD 5,457,229 in the same period of 2018[42] - Treatment services revenue reached SGD 3,613,779, up 9.8% from SGD 3,292,098 in 2018[42] - Medical examination services revenue increased by 25.8% to SGD 2,020,776 from SGD 1,606,447 in 2018[42] - The company reported a profit attributable to owners of SGD 556,884 for the six months ended June 30, 2019, compared to a loss of SGD 1,515,956 in the same period of 2018[46] - Basic earnings per share for the period was SGD 0.12, compared to a loss per share in the previous year[46] Assets and Liabilities - Total assets increased to SGD 15.8 million as of June 30, 2019, compared to SGD 14.2 million as of December 31, 2018[15] - Cash and cash equivalents rose to SGD 13.5 million from SGD 12.4 million at the end of 2018[15] - Trade receivables increased significantly to SGD 127,773 from SGD 55,787 in the previous year[15] - Total equity increased to SGD 13.1 million as of June 30, 2019, compared to SGD 12.6 million at the end of 2018[16] - The group reported total liabilities of SGD 2.7 million, up from SGD 1.5 million at the end of 2018[16] - Trade payables rose significantly to SGD 1,002,955 as of June 30, 2019, compared to SGD 388,119 at the end of 2018[57] - The company reported accrued operating expenses of SGD 658,295 as of June 30, 2019, up from SGD 556,914 at the end of 2018[58] Cash Flow and Capital Management - The company reported a net cash inflow from operating activities of SGD 1,436,291 for the six months ended June 30, 2019, compared to a cash outflow of SGD 1,021,717 in the same period of 2018[21] - Cash and cash equivalents as of June 30, 2019, totaled SGD 13,526,026, an increase from SGD 12,370,343 at the end of 2018[54] - The company has no bank borrowings as of June 30, 2019, consistent with the previous year[81] - The company’s retained earnings as of June 30, 2019, stood at SGD 1,104,685, reflecting an increase from SGD 547,801 at the beginning of the year[18] - The company’s capital management objective is to ensure the group can continue as a going concern while providing returns to shareholders[36] Corporate Governance and Compliance - The audit committee, consisting of three independent non-executive directors, has reviewed the unaudited condensed consolidated financial statements and found them compliant with applicable accounting standards[121] - The company is committed to maintaining high standards of corporate governance and has adopted all applicable code provisions of the GEM Listing Rules[115] - The company has established an audit committee to oversee financial reporting and risk management processes[121] - No directors or controlling shareholders have interests in any competing businesses during the reporting period[114] - The company has complied with the GEM Listing Rules regarding securities trading by directors[116] Future Plans and Investments - The company is focused on maintaining operational efficiency and exploring new market opportunities to drive future growth[10] - The net proceeds from the IPO of approximately SGD 9.1 million will be used for future expansion and business growth in Singapore[69] - The company operates seven DTAP centers and two SA centers, with plans to open another center in Bukit Timah[68] - The company has plans to open a new DTAP treatment center in the northeastern part of Singapore, postponed to the first half of 2021 due to space availability[102] - The company spent SGD 241,000 on renovations for three new DTAP treatment centers during the period[95] - The company allocated SGD 63,000 for upgrading its information technology infrastructure and systems as of June 30, 2019[99] Risks and Contingencies - The company has not faced any major foreign exchange risks as all transactions are conducted in Singapore dollars[89] - The company has not utilized any hedging contracts for speculative activities during the period[90] - There are no significant contingent liabilities reported as of June 30, 2019[87] - There are no significant events affecting the company reported after June 30, 2019[93]

Financial Performance - The group recorded revenue of SGD 2.8 million for the three months ended March 31, 2019, representing an increase of approximately 10.5% compared to SGD 2.6 million for the same period in 2018[6]. - The net profit for the period was approximately SGD 0.3 million, unchanged from the previous year, primarily due to increased employee and operating expenses offsetting revenue growth[6]. - The group reported a gross profit of SGD 323,000 for the period, slightly up from SGD 307,000 in the previous year[9]. - Total comprehensive income attributable to owners of the company for the period was SGD 268,000, compared to SGD 255,000 in the previous year[9]. - Revenue increased by approximately SGD 0.3 million or 10.5% year-on-year, reaching about SGD 2.8 million for the quarter ended March 31, 2019[31]. - Net profit attributable to owners was approximately SGD 0.3 million, consistent with the same period last year[35]. - Earnings per share decreased to 0.05 Singapore cents from 0.06 Singapore cents year-on-year, with issued shares increasing from 390 million to 520 million[25]. Expenses and Costs - Employee benefits expenses increased to SGD 916,000 from SGD 713,000 in the previous year, reflecting higher operational costs[9]. - Employee benefits expenses rose by approximately SGD 0.2 million or 28.5% to about SGD 0.9 million, primarily due to hiring for new treatment centers[33]. - Other operating expenses increased by approximately SGD 0.3 million, attributed to higher marketing and legal costs post-IPO[34]. Dividends and Equity - The company did not declare any dividends for the period, consistent with the previous year[7]. - The company has no bank borrowings and maintains a strong liquidity position with no significant contingent liabilities[39][43]. - The company’s total equity as of March 31, 2019, was SGD 12.84 million, an increase from SGD 12.57 million at the beginning of the year[11]. - No dividends were declared for the period, consistent with the previous year[36]. Business Operations and Expansion - Medical services revenue included SGD 1.7 million from treatment services, SGD 0.9 million from medical examination services, and SGD 0.3 million from consultation services[19]. - The company opened two new treatment centers during the period, expanding its network under the "Dr. Tan & Partners" brand[27]. - The group continues to focus on expanding its healthcare services in Singapore, leveraging its existing facilities and expertise[14]. Compliance and Governance - The financial statements were prepared in accordance with International Financial Reporting Standards and GEM listing rules, ensuring compliance and transparency[15]. - The company has complied with all applicable corporate governance codes as per GEM Listing Rules[60]. - The audit committee, consisting of three independent non-executive directors, has reviewed the financial statements and found them compliant with applicable accounting standards[65]. - There were no interests held by directors or controlling shareholders in any competing businesses during the reporting period[58]. Shareholding Structure - As of March 31, 2019, the company had a total of 520,000,000 shares issued[52]. - Dr. Chen holds 390,000,000 shares, representing 75% of the company's issued shares[56]. - Cher Sen Holdings Limited, controlled by Dr. Chen, owns 390,000,000 shares, also accounting for 75% of the issued shares[56]. - Dr. Chen is the beneficial owner of 50,000 shares in Cher Sen, representing 100% of that entity[53]. - No other entities, apart from those disclosed, held any significant interests in the company's shares as of March 31, 2019[57]. Other Information - The company has not disclosed any new product developments or market expansions in the provided documents[64]. - No securities were repurchased or sold by the company during the reporting period[63]. - The management emphasizes ongoing investment in technology to maintain competitive advantages, particularly in the medical aesthetics sector[28].

Financial Performance - The group's revenue for the fiscal year ended December 31, 2018, was approximately SGD 10.4 million, an increase of about 4.7% compared to SGD 10.0 million for the fiscal year ended December 31, 2017[10]. - The group recorded a loss of approximately SGD 0.7 million for the fiscal year, compared to a profit of SGD 2 million in the previous fiscal year, primarily due to non-recurring listing expenses of about SGD 2.1 million[10]. - Adjusted profit for the fiscal year was approximately SGD 1.4 million, down from SGD 2.7 million in the previous fiscal year, mainly due to costs incurred post-listing[10]. - The group's total revenue for the year was approximately SGD 10,421,000, an increase of about SGD 465,000 or 4.7% compared to SGD 9,957,000 in FY2017[16]. - Revenue from medical examination services increased by SGD 100,000 to SGD 3,017,000, maintaining a stable contribution percentage of 29%[19]. - Revenue from treatment services rose by SGD 800,000 to SGD 6,263,000, with its contribution percentage increasing from 54.8% in FY2017 to 60.1% in FY2018[19]. - The group recorded a loss of approximately SGD 731,000 for the year, a decline of about SGD 2.7 million compared to a profit of SGD 2 million in FY2017[34]. - Listing expenses totaled approximately SGD 3.9 million for the year, significantly up from SGD 743,000 in FY2017[35]. - The group did not declare a final dividend for the year, following a total dividend distribution of approximately SGD 2.2 million in FY2017[38]. Revenue Breakdown - Revenue from consultation services, treatment services, and medical examination services were approximately SGD 1.1 million, SGD 6.3 million, and SGD 3.0 million, respectively, accounting for 10.1%, 60.0%, and 29.0% of total revenue[15]. Expenses and Costs - Employee benefits expenses increased by SGD 861,000 or 30.8% to SGD 3,659,000 due to an increase in the number of employees[26]. - Other operating expenses grew by approximately SGD 1,788,000 or 87.8% to about SGD 3,825,000, largely due to increased listing expenses[30]. - Employee costs for the year amounted to approximately SGD 3.7 million, up from SGD 2.8 million in the fiscal year 2017[47]. Assets and Equity - Total equity as of December 31, 2018, was approximately SGD 12.6 million, up from SGD 1.7 million in the fiscal year 2017[39]. - Cash and bank balances as of December 31, 2018, were approximately SGD 12.4 million, compared to SGD 2.0 million in the fiscal year 2017[39]. - Net current assets as of December 31, 2018, were approximately SGD 11.7 million, an increase from SGD 876,000 in the fiscal year 2017[39]. - The capital debt ratio as of December 31, 2018, was 0.0%, consistent with the fiscal year 2017[39]. Future Plans and Expansion - The net proceeds from the listing amounted to approximately SGD 9.1 million, which will be used for future expansion and business growth in Singapore[11]. - The company aims to expand its market share and enhance the DTAP brand reputation in the competitive healthcare services industry in Singapore[15]. - The company has delayed the opening of a new DTAP clinic in western Singapore to mid-2019 due to the availability of suitable rental space, with approximately SGD 1.1 million from the IPO proceeds remaining unutilized[61]. - The company has begun the design work for IT infrastructure and systems for the clinics, having selected suppliers and paid a deposit of SGD 57,000[63]. - The company has identified Holland Village as a suitable location for the new DTAP clinic, with renovations planned[63]. Governance and Leadership - The company has a strong governance structure with independent non-executive directors overseeing key committees such as audit, nomination, and remuneration[76][78]. - The company has established a strong foundation for future growth with experienced leadership in both medical and financial sectors[81][82]. - The board includes members with diverse backgrounds in finance, healthcare, and technology, contributing to a well-rounded strategic direction[76][82]. - The independent directors provide independent judgment on strategies, policies, and accountability standards, ensuring robust governance[76][78]. - The company is committed to maintaining high standards of corporate governance and regularly reviews its practices[146]. Committees and Meetings - The company has established three committees: Audit Committee, Nomination Committee, and Remuneration Committee, to oversee specific aspects of its affairs[186]. - The Audit Committee monitors the integrity of the company's financial statements and reviews significant judgments related to financial reporting[190]. - The Nomination Committee is tasked with reviewing the company's corporate governance policies and practices, making recommendations to the board[195]. - The Remuneration Committee reviewed matters related to the remuneration of directors and senior management during a meeting on March 27, 2019, providing recommendations to the board[199]. Shareholder Information - As of December 31, 2018, a director held 390 million shares, representing 75% of the company's issued shares, through a controlled corporation[135]. - The company maintains a sufficient public float, with at least 25% of its issued shares held by the public[148]. - The company has not repurchased any of its listed securities during the period[108].